Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221518 | 0.93 | ITGAV (0.58) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6285176 | 0.80 | ITGAV (0.53) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6289069 | 0.80 | ITGAV (0.51) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6729630 | 0.78 | ITGAV (0.59) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20025245 | 0.76 | ITGAV (0.64) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL19953598 | 0.74 | ITGAV (0.73) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL19953599 | 0.74 | ITGAV (0.73) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6221639 | 0.74 | LTA4H (0.47) | ITGB3ITGA2B | |
| SCHEMBL20025156 | 0.73 | ITGAV (0.69) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL6224024 | 0.73 | ITGAV (0.65) | ITGAVITGB3ITGB1ITGA5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | ITGAV 296/4885ITGB3 220/4885ITGB1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.